Spot-on Pharma Consulting ApS: Financial statements 2025
CVR: 44288729
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Spot-on Pharma Consulting ApS (CVR 44288729) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 1,449,337 and a net result of DKK 619,331. Equity in the 2025 report amounted to DKK 865,620. The solvency ratio was 80.8%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 1,449,337
- Profit/Loss
- DKK 619,331
- Equity
- DKK 865,620
- Total Assets
- DKK 1,070,849
- Employees
- 1
Official annual report
How creditworthy is Spot-on Pharma Consulting ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Spot-on Pharma Consulting ApS has published its interim report for the period September 8, 2023 to December 31, 2024.
About Spot-on Pharma Consulting ApS
Spot-on Pharma Consulting ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2023. The company is registered under the industry Rådgivende ingeniøraktiviteter inden for produktions- og maskinteknik. The management consists of Erik Steffensen. The company is owned by Engtofte Holding ApS. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 1,449,337 and a net result of DKK 619,331. Equity in the 2025 report amounted to DKK 865,620.